Abstract
Global health efforts such as malarial control require efficient pharmaceutical supply chains to ensure effective delivery of quality-assured medicines to those who need them. However, very little is currently known about decision-making processes within antimalarial supply chains and potential vulnerabilities to substandard and falsified medicines. Addressing this gap, we report on a study that investigated decision-making around the stocking of antimalarial products among private-sector medicine retailers in Ghana. Licensed retail pharmacies and over-the-counter (OTC) medicine retail outlets were sampled across six regions of Ghana using a two-stage stratified sampling procedure, with antimalarial medicines categorised as ‘expensive,’ ‘mid-range,’ and ‘cheaper,’ relative to other products in the shop. Retailers were asked about their motivations for choosing to stock particular products over others. The reasons were grouped into three categories: financial, reputation/experience and professional recommendation. Reputation/experience (76%, 95% CI 72.0% to 80.7%) were the drivers of antimalarial stocking decisions, followed by financial reasons (53.2%, 95% CI 48.1% to 58.3%) and recommendation by certified health professionals (24.7%, 95% CI 20.3% to 29.1%). Financial considerations were particularly influential in stocking decisions of cheaper medicines. Moreover, pharmacies and OTCs without a qualified pharmacist were significantly more likely to indicate financial reasons as a motivation for stocking decisions. No significant differences in stocking decisions were found by geographical location (zone and urban/rural) or outlet (pharmacy/OTC). These findings have implications for the management of antimalarial quality across supply chains in Ghana, with potentially important consequences for malaria control, particularly in lower-income areas where people rely on low-cost medication.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference42 articles.
1. Study on the public health & socioeconomic impact of SF medical products. Geneva World Health Organisation; 2017.
2. WHO . WHO global surveillance and monitoring system for substandard and falsified medical products. Geneva: World Health Organization, 2017b. Available: https://apps.who.int/iris/handle/10665/326708
3. Ozawa S , Evans DR , Bessias S , et al . Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open 2018;1:e181662. doi:10.1001/jamanetworkopen.2018.1662
4. A new handheld device for the detection of falsified medicines: demonstration on falsified artemisinin-based therapies from the field;Wilson;Am J Trop Med Hyg,2017
5. Quality of artemisinin-based combination therapy for malaria found in Ghanaian markets and public health implications of their use;Tivura;BMC Pharmacol Toxicol,2016